CSE « AGORACOM Small-cap Investor Relations Blog

Agoracom Blog Home

Posts Tagged ‘CSE’

VIDEO: CEO LiveChat – ThreeD Capital $IDK.ca $IDKFF $IP.ca $IPNFF $GMBL

Posted by AGORACOM-JC at 3:21 PM on Tuesday, September 1st, 2020

Why ThreeD Capital?

Discovering Great Disruptive Companies

ThreeD Capital provides investors with significant exposure to ground floor opportunities in

Small cap stocks in their very early stages;
Disruptive Technologies

that would otherwise be impossible for 99% of investors to participate in. There is quite simply no other investment vehicle like it in the Canadian small cap space.

Best of all, investors get to invest in ThreeD Capital under the leadership of one of the greatest investors in Canadian history – Sheldon Inwentash, the Founder, Chairman and CEO. When Sheldon Inwentash speaks, listeners stand to make a lot of money. His track record speaks for itself.

Tags: artificial intelligence, blockchain, CSE, Disruptive companies, esports, gold, IOT, shrooms, stocks, tsx
Posted in Featured, ThreeD, ThreeD Capital | Comments Off on VIDEO: CEO LiveChat – ThreeD Capital $IDK.ca $IDKFF $IP.ca $IPNFF $GMBL

PyroGenesis $PYR.ca Participates in $HPQ.ca Non-Brokered Private Placement Financing $IDK.ca $DUK $XEL $NEE

Posted by AGORACOM-JC at 8:26 AM on Tuesday, September 1st, 2020

Announced that it is closing a non-brokered private placement of 4,500,000 units (“Unit”) at $0.60 per Unit for gross proceeds of $2,700,000 with the two following Placees:

PyroGenesis Canada Inc, (TSX-V: PYR), a high-tech company, that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products has subscribed for 4,000,000 units in the placement for a gross proceeds of $2,400,000;
THREED CAPITAL INC. (CSE: IDK) (OTTCBB: IDKFF) a Canadian venture capital firm that invests in disruptive companies has subscribed for 500,000 units in the placement for a gross proceeds of $300,000.

MONTREAL, Sept. 01, 2020 — HPQ Silicon Resources Inc. (“HPQ” or “the Company”) TSX-V: HPQ; FWB: UGE; Other OTC : URAGF; is pleased to announce that it is closing a non-brokered private placement of 4,500,000 units (“Unit”) at $0.60 per Unit for gross proceeds of $2,700,000 with the two following Placees:

PyroGenesis Canada Inc, (TSX-V: PYR), a high-tech company, that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products has subscribed for 4,000,000 units in the placement for a gross proceeds of $2,400,000;
THREED CAPITAL INC. (CSE: IDK) (OTTCBB: IDKFF) a Canadian venture capital firm that invests in disruptive companies has subscribed for 500,000 units in the placement for a gross proceeds of $300,000.

“This transaction is a further demonstration of the strength of the HPQ – PyroGenesis cooperation as we develop both the PUREVAP™ Quartz Reduction Reactor (QRR) and the PUREVAP™ Nano Silicon Reactor (NSiR) processes. Furthermore, the participation of legendary Venture Capital Financier Sheldon Inwentash in a Private Placement that values HPQ market capitalization over the $150 Million threshold is strong vote of confidence in what we are doing,” said Bernard Tourillon, President & CEO of HPQ Silicon. “Our PUREVAP™ processes open up unique business opportunities with multibillion-dollar addressable markets for HPQ, PyroGenesis and our shareholders, as we strive to deliver the critical Silicon nano-materials required by the surging Li-ion battery market and other renewable energy sectors.”

“It is indeed a pleasure to participate in this private placement and increase our position in HPQ,” said P. Peter Pascali CEO and Chairman of PyroGenesis Canada Inc. “Not only do we find this to be a unique opportunity to invest in a business that has enormous potential for growth, but one that is supported by a visionary management and Board. We are confident that this investment will play out very well for us and our investors, and we look forward to consider adding to our position should the opportunity arise in the future.”

In addition to participating in the Placement, HPQ is pleased to announce that THREED Capital Inc CEO Sheldon Inwentash has agreed to act as a strategic advisor to HPQ management as we embark in the start of this new and exciting phase of our development.

Placement Terms: Each Unit will be comprised of one (1) common share and one (1) common share purchase warrant (“Warrant”) of the Company. Each Warrant will entitle the Subscribers to purchase one common share of the capital stock of the Company at an exercise price of $ 0.61 for a period of 36 months from the date of closing of the placement. Each share issued pursuant to the placement will have a mandatory four (4) month and one (1) day hold period from the date of closing of the placement. The Placement is subject to standard regulatory approvals.

About Silicon

Silicon (Si), also known as silicon metal, is one of today’s strategic materials needed to fulfil the Renewable Energy Revolution (“RER”) presently under way. Silicon does not exist in its pure state; it must be extracted from quartz (SiO2), in what has historically been a capital and energy intensive process.

About HPQ Silicon

HPQ Silicon Resources Inc. (TSX-V: HPQ) is a Canadian producer of Innovative Silicon Solutions, based in Montreal, building a portfolio of unique high value specialty silicon products needed for the coming RER.

Working with PyroGenesis Canada Inc. (TSX-V: PYR), a high-tech company that designs, develops, manufactures and commercializes plasma – based processes, HPQ is developing:

The PUREVAP™ “Quartz Reduction Reactors” (QRR), an innovative process (patent pending), which will permit the one step transformation of quartz (SiO2) into high purity silicon (Si) at reduced costs, energy input, and carbon footprint that will propagate its considerable renewable energy potential;
° HPQ believes it will become the lowest cost (Capex and Opex) producer of silicon (Si) and high purity silicon metal (3N – 4N Si);
The PUREVAP™ Nano Silicon Reactor (NSiR), a new proprietary process that can use different purities of silicon (Si) as feedstock, to make spherical silicon nanopowders and nanowires;
° HPQ believes it can also become the lowest cost manufacturer of spherical Si nanopowders and silicon-based composites needed by manufacturers of next-generation lithium-ion batteries;
° During the coming months, spherical Si nanopowders and nanowires silicon-based composite samples requested by industry participants and research institutions’ will be produced using PUREVAP™ SiNR.

HPQ is also working with industry leader Apollon Solar of France to:

Use their patented process and develop a capability to produce commercially porous silicon (Si) wafers and porous silicon (Si) powders;
° The collaboration will allow HPQ to become the lowest cost producer of porous silicon wafers for all-solid -state batteries and porous silicon powders for Li-ion batteries.
° The plan is to deliver porous Si wafer to a battery manufacturer (under NDA) for testing in 2020.

This News Release is available on the company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

Disclaimers:

The Corporation’s interest in developing the PUREVAP™ QRR and any projected capital or operating cost savings associated with its development should not be construed as being related to the establishing the economic viability or technical feasibility of any of the Company’s Quartz Projects.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s on-going filings with the security’s regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information contact

Bernard J. Tourillon, Chairman, President and CEO Tel (514) 907-1011
Patrick Levasseur, Vice-President and COO Tel: (514) 262-9239
http://www.hpqsilicon.com Email: [email protected]

Tags: CSE, High Purity Quartz, High purity silicon, nanomaterials, PUREVAP, stocks
Posted in HPQ-Silicon Resources Inc. | Comments Off on PyroGenesis $PYR.ca Participates in $HPQ.ca Non-Brokered Private Placement Financing $IDK.ca $DUK $XEL $NEE

Datametrex $DM.ca Applies to Health Canada for 5 Minute Fast Antigen Kit

Posted by AGORACOM-JC at 8:18 AM on Tuesday, September 1st, 2020

http://www.smallcapepicenter.com/DM%20square.png

Announced that the Company has submitted a Medical Devices Interim Order Request Form to approve PCL, Inc.’s COV05 COVID19 Rapid Antigen Detection Kits to Health Canada
Application is made under IO Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 pursuant to subsection 30.1(1) of the Food and Drugs Act signed by the Minister of Health on August 24, 2020, for PCLCOV05 COVID19 Rapid Antigen Detection Kits.

TORONTO, Sept. 01, 2020 – Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF ) is pleased to announce that the Company has submitted a Medical Devices Interim Order (“IO”) Request Form to approve PCL, Inc.’s (“PCL”) COV05 COVID19 Rapid Antigen Detection Kits to Health Canada.

This application is made under IO Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 pursuant to subsection 30.1(1) of the Food and Drugs Act signed by the Minister of Health on August 24, 2020, for PCLCOV05 COVID19 Rapid Antigen Detection Kits. This IO will allow Health Canada to issue expedited review and approval for the sale of these test kits in Canada.

The Company has represented to Health Canada that it will be able to provide a minimum first order of 200,000, followed by an additional 200,000 units on a weekly basis. Any purchase of the test kits by the Canadian government is conditional on prior receipt of Health Canada approval.

These test kits are suitable for point of care tests. No extra equipment is needed. They are simple to use and results are available in 10 minutes.

“According to the manufacturer, PCL, this test can detect antigens of COVID-19 from a swab in the nose and throat to provide results in 5-10 minutes with over 86% accuracy,” said Marshall Gunter, CEO of Datametrex. “These almost-instant kits can be easily used at home. With the rise of cases in the United States and throughout the world, we at Datametrex believe it is critical to test and protect.”

View the PCL Antigen test manual video by clicking the link: PCL COVID-19 ANTIBODY TEST – COV0

According to PCL the clinical sensitivity (confirmed the actual positive of the approved person where approved person tested positive with a PCR nucleic test) is 86.49% and the clinical specificity (confirmed the actual negative of the negative person where the negative person tested negative with a PCR nucleic test) is 97.87%*. Early detection using rapid tests will also provide further protection to Canada’s front-line workers, especially health care professionals.

The following certifications have been awarded to these PCL Antigen Test Kits: CE Certificate, Korea KPMG, FIND Listed, UNGM Supplier. Countries includes the EU, 2 countries in the Middle East- Qatar and UAE, India, Russia, 3 countries in Latin America- Guatemala, Ecuador, and Colombia.

The PCL Inc Antigen Detection kit has the CE Certificate meaning that the manufacturer and products have met EU declaration of standards for health, safety, and environmental protection, allowing this product to be sold within the 22 countries in the European Economic Area.

Health Canada must approve these COVID-19 test kits before they can be used in Canada. The Company plans to sell these kits in all countries where the kits have been approved for sale. Datametrex anticipates that it will have little or no upfront costs associated with importing these test kits. Assuming Health Canada approves the test kits and they are subsequently purchased by the Canadian government, manufacturer will ship the test kits directly to the Canadian government or hospitals, and Datametrex will not be involved in the shipping, warehousing or distribution process.

* Clinical Accuracy

The clinical performance of the PCL COVID-19 Ag Rapid FIA was evaluated in two different institutions compared to RT-PCR positive cases. Positive percent is 86.49% (95% CI: 70.43-94.92%) and negative percent agreement is 97.87% (95% CI: 87.28%-99.89%) in the PCL COVID-19 Ag Ripid FIA.

COVID-19 Ag Ripid FIA.	RT – PCR	PPA (%)	NPA (%)
POS	NEG
Site 1	POS	20	0	100.00	96.00
NEG	0	20
Total	20	20
Site 2	POS	12	1	70.59	100.00
NEG	5	26
Total	17	27
Total	POS	32	1	86.49	97.87
NEG	5	46
Total	37	47

About Datametrex

Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Tags: covid19, CSE, datametrex, investments, Lotte, Lotte Home Shopping, PCL
Posted in Datametrex AI Limited, Featured | Comments Off on Datametrex $DM.ca Applies to Health Canada for 5 Minute Fast Antigen Kit

ThreeD Capital Inc. $IDK.ca $IDKFF Provides Corporate Developments $IP.ca $IPNFF $GMBL

Posted by AGORACOM-JC at 7:39 AM on Tuesday, September 1st, 2020

Company is pleased to announce it is now disclosing the number of junior resource and technology investments on its newly designed website and will update these figures at the commencement of each month
In the last month, ThreeD increased the number of junior resource investments from 12 to 15, representing a 25% increase month over month
The Company plans to continue to grow its junior resource portfolio for the foreseeable future

TORONTO, Sept. 01, 2020 — ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQB:IDKFF) a Canadian based venture capital firm that invests in disruptive companies and promising junior resources companies, is pleased to provide a general corporate update to shareholders.

ThreeD is actively investing in the junior resource sector and has significantly grown its number of junior resource investments for the last 3 consecutive months.

The Company is pleased to announce it is now disclosing the number of junior resource and technology investments on its newly designed website and will update these figures at the commencement of each month. In the last month, ThreeD increased the number of junior resource investments from 12 to 15, representing a 25% increase month over month. The Company plans to continue to grow its junior resource portfolio for the foreseeable future.

ThreeD previously reported in its continuous disclosure documents that it had sold pursuant to a share purchase agreement dated November 15, 2019, an aggregate of 13,500,000 common shares of New Found Gold Corp. to a third party purchaser at a price of $0.08 per share for aggregate proceeds of $1,080,000. The Company has since commenced a legal action claiming rescission of the transaction or, in the alternative, damages in the approximate amount of $16,000,000 or the present value of the common shares. The Company is currently arranging with the third party dates and times for discoveries in this action. The Company believes that the purchaser was in possession of information material to the transaction that was not disclosed at the time. It is not determinable if the Company will be successful in its claim or, if successful, the amount of damages that may be awarded, if any.

About ThreeD Capital Inc.

ThreeD is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the Junior Resources, Artificial Intelligence, Blockchain, Esports, Renweable Technology, Internet of Things, & Nanotechnology sectors. ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and is actively involved with investees by advising and leveraging ThreeD’s powerful network.

Forward-Looking Statements

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of Canadian securities laws including, without limitation, statements with respect to the legal action concerning the common shares of New Found Gold Corp. (the “Litigation”). All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur including, without limitation, risks relating to the timing, costs and potential outcome of the Litigation. Although the Company believes that the expectations reflected in the forward looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company’s actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

For further information:

Gerry Feldman, CPA, CA

Chief Financial Officer and Corporate Secretary
[email protected]

Phone: 416-941-8900 ext 106

Tags: artificial intelligence, blockchain, CSE, Disruptive companies, esports, gold, IOT, shrooms, stocks, tsx
Posted in Featured, ThreeD, ThreeD Capital | Comments Off on ThreeD Capital Inc. $IDK.ca $IDKFF Provides Corporate Developments $IP.ca $IPNFF $GMBL

Empower Clinics $CBDT.ca Announces Acquisition of Medical Diagnostics Laboratory $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:06 AM on Tuesday, September 1st, 2020

Empower intends to acquire Kai Medical Laboratory, a state-of-the-art diagnostics laboratory located in the medical district of Dallas, TX to advance COVID-19 national testing programs

Entered into a non-binding term sheet to acquire the business of Kai Medical Laboratory, LLC, by way of a share or asset acquisition, subject to due diligence and customary closing conditions
Kai Medical Laboratory is a high-complexity CLIA and COLA accredited Laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups
Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology

VANCOUVER, BC / September 1, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (Frankfurt:8EC) (OTCQB:EPWCF) (“Empower” or the “Company“) today announces it has entered into a non-binding term sheet to acquire the business of Kai Medical Laboratory, LLC (“Kai Medical Laboratory“), by way of a share or asset acquisition, subject to due diligence and customary closing conditions.

Kai Medical Laboratory is a high-complexity CLIA and COLA accredited Laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology. These tests are done under the supervision of its well-qualified and highly experienced scientists, medical professionals, and pharmacists. https://www.kaimedicallaboratory.com

Kai Medical Laboratory has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.

To further assist with COVID-19 testing, Kai Medical Laboratory has also developed two key programs in Texas and Arizona. The first program is a direct-to-consumer program that leverages the ability of various healthcare providers to order and administer both the RT-PCR test and the Antibody test. This increases the ability of the general population to be tested, in certain circumstances. The second is an Employer COVID-19 Compliance Program (ECCP) for business owners and employer groups to enable them to test and monitor their employees.

Texas program https://www.testtexasnow.com

Arizona program https://www.covidtest2u.com

Currently the lab has the capacity to complete in excess of 2,000 RT-PCR tests in one eight-hour shift by utilizing its Thermo Fisher QuantStudio 12k Flex testing machine. The lab also utilizes a Roche Cobas 6000 for COVID-19 Antibody testing, ensuring that Kai Medical Laboratory has the capability and capacity to serve a broad range of clients and test methods.

“Adding Kai Medical Laboratory to the Empower Clinics family enables us to dramatically expand COVID-19 testing capability and deliver phase four of our national rollout plan” said Steven McAuley, Empower’s Chairman & CEO. “Kai Medical has a newly built high-complexity lab offering a wide array of testing services, that together we will leverage to serve the massive demand for national COVID testing in the U.S. Further, as flu season arrives and a potential second-wave of COVID takes hold, the technical infrastructure of Kai Medical allows Empower to capture testing demand and the additional growth revenues associated with it.”

The driving force behind Kai Medical Laboratory’s remarkable growth and success is Yoshi Tyler. Yoshi has a passion for being an entrepreneur, and overtime, she found her true calling in healthcare. Driven by this interest, she pursued her career in the healthcare industry for more than two decades. She helmed leadership positions at a Fortune 500 pharmaceutical company for over thirteen years. These leadership experiences provided her with in-depth knowledge and industry insights that helped her to lead Kai Medical Laboratory towards growth.

The Kai Medical Laboratory team includes key roles including Principal Scientist, Director of Operations, Molecular Scientist, Quality Assurance, Lab Director and other critical roles.

“Kai Medical Laboratory is inspired by science and built on integrity. Our mission is to change healthcare through science & innovative quality care by providing value-added services, accuracy, and consistency. Our unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to a new standard in healthcare,” says Yoshi Tyler, the owner, and CEO of the company.

The proposed acquisition includes an 8,000 sq. ft. medical laboratory including covered drive up testing center, with premium testing and laboratory equipment, cash and current assets with a value in excess of $1,750,000.00 USD and a corporate office, both located in the heart of the medical district in Dallas, TX. Under the proposed terms Empower will assume a $1,200,000.00 USD Small Business Administration (SBA) equipment loan, a $150,000.00 SBA Economic Injury Disaster Loan and short-term liabilities of up to $250,000.00 at closing. In addition, Empower will issue 1,000,000 Company stock options to the Vendors, subject to the terms and conditions as set out in the Company Stock Option Plan.

Market Leading Technology Kai Medical Laboratory utilizes state-of-the-art instrumentation, preeminent testing methodologies, and laboratory services enabling high-complexity accredited laboratory testing solutions, providing some of the following key instrument testing capabilities:

Thermo Fisher – QuantStudio 12K Flex
- COVID-19 testing
- Cannabis Testing
- Clinical Genomics
Roche Cobas 6000
- COVID-19 Antibody testing
- Clinical Chemistry/Endocrinology
AB SCIEX 6500+ – Liquid Chromatography Mass Spectrometry
- Clinical Chemistry/Endocrinology
- Agriculture/Cannabis testing
AB SCIEX 4500 – Liquid Chromatography Mass Spectrometry
- Urine Toxicology
- Cannabis testing
SYSMEX XN-550
- Hematology

USA COVID-19 Data as at August 31, 2020

TOTAL CASES: 5,972,356

TOTAL DEATHS: 182,622

CASES IN LAST 7 DAYS: 289,865

ARIZONA as at August 31, 2020

CONFIRMED CASES: 199,984

PROBABLE CASES: 1,713

TOTAL CASES: 201,661

CASES IN LAST 7 DAYS: 3,558

CASES/100K: 1,769

DEATHS/100K: 70

TEXAS as at August 31, 2020

TOTAL CASES: 610,354

CASES IN LAST 7 DAYS: 32,817

CASES/100K: 2,126

DEATHS/100K: 46

(CLIA) The Clinical Laboratory Improvement Amendments regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing.

(COLA) is the premier clinical laboratory accreditation, education and consultation organization. An independent accreditor whose practical, educational standards have a positive and immediate impact on patient care. http://www.cola.org

The transaction is expected to be structured on a tax efficient basis, and otherwise in accordance with the requirements of requisite securities laws and the policies of the CSE. Empower has agreed to enter into employment agreements with Yoshi Tyler and Michael Haines, each having an initial term of two years.

Completion of the transaction will be subject to various conditions, including entry into a definitive agreement, completion of due diligence, and receipt of all required shareholder, manager, third party and regulatory approvals, including approval of the CSE. Closing of the transaction is expected to occur prior to October 15, 2020.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative.

ABOUT KAI MEDICAL LABORATORY

Our mission is to change healthcare through science & innovative quality care by providing value added services, accuracy, and consistency. Our unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to a new standard in patient care. Kai Medical Laboratory is located in the Dallas Medical District in close proximity to some of the largest healthcare groups in the U.S. including Parkland Hospital, UT Southwestern, Children’s Medical Center, Baylor Scott & White Health (Dallas), Tenet Healthcare (Dallas), CHRISTUS Healthcare (Dallas).

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein

Director
[email protected]
720-352-1398

Investors: Steven McAuley

CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the proposed acquisition of Sun Valley; the proposed transaction terms; the expected number of clinics and patients following the closing; the future potential success of Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: CBD, covid19, CSE, Dosed Movie, Dosed Wellness, Hemp, investments, Kai Medical Laboratory, small cap, small cap stocks, stocks, tsx
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Announces Acquisition of Medical Diagnostics Laboratory $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Datametrex $DM.ca Appoints New Chief Financial Officer

Posted by AGORACOM-JC at 7:57 PM on Monday, August 31st, 2020

Announced the appointment of Don Shim, CPA, CA as the new Chief Financial Officer
This new addition to the Company’s executive leadership team brings nearly 20 years of financial experience in accounting and financial control along with a combination of private and public companies in a variety of industries.

TORONTO, Aug. 31, 2020 — Datametrex AI Limited (“Datametrex” or the “Company“) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce the appointment of Don Shim, CPA, CA as the new Chief Financial Officer (“CFO”).

This new addition to the Company’s executive leadership team brings nearly 20 years of financial experience in accounting and financial control along with a combination of private and public companies in a variety of industries. These include cannabis, resource, and financial services. Don will work to ensure Datametrex’s financial health through strategic planning and management of the company’s finances.

Mr. Shim has led a successful accounting and finance career in both the US and Canada. He brings a wealth of knowledge to the team with his expertise in auditing publicly- traded junior mining companies and high-tech industries. Member of the Chartered Professional Accountants of British Columbia and a Certified Public Accountant registered in the State of Illinois, United States.
Audit partner on numerous audit engagements for various publicly traded companies, primarily focusing on junior mining, oil and gas, pharmaceutical, and high-tech industries.
Mr. Shim also assisted various start-up companies in achieving public listings on the TSX Venture Exchange, Canadian Securities Exchange and the OTC Market.
In addition, Mr. Shim teaches accounting at a local college in Vancouver and acts as a facilitator at CPA Western School of Business, mentoring CPA candidates enrolled in the CPA Professional Education Program.

“I am thrilled to join Datametrex and this impressive leadership team with a history of growing great companies, and I am happy to be a part of this enterprise,” said Don.

“On behalf of the executive team and our Board of Directors, I would like to thank Steve Kang for his dedication and hard work during his tenure as CFO. I wish Steve nothing but success in his future endeavours,” said Paul Haber, audit committee chair of the Company.

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Tags: covid19, CSE, datametrex, investments, Lotte, Lotte Home Shopping, PCL
Posted in Datametrex AI Limited | Comments Off on Datametrex $DM.ca Appoints New Chief Financial Officer

END OF DAY ALERT – Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Up 30% To All-Time Closing High On 1.9M Shares $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 5:21 PM on Monday, August 31st, 2020

Tags: BioCloud, COVID-19, CSE, energy conservation, google nest, stocks, tsx, tsx-v
Posted in Kontrol Energy Corp. | Comments Off on END OF DAY ALERT – Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Up 30% To All-Time Closing High On 1.9M Shares $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Reports Second Quarter 2020 Results $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 5:01 PM on Monday, August 31st, 2020

Kontrol continues to focus on strengthening its Balance Sheet. The Company’s cash position at the end of Q2 is approximately $1.8 Million
During the second quarter of 2020 the Company announced the commencement of a non-brokered private placement (with an exchange of units) of up to $5.8 million principal amount 8% unsecured (and non-convertible) debentures maturing on October 31, 2022
Company is developing its BioCloud technology and has a achieved a number of significant milestones, including the initial funding from the Government, positive testing of the detection mechanism, and positive testing of the BioCloud fully operational prototype.

TORONTO, ON / August 31, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company”) a leader in the energy efficiency sector through IoT, Cloud and SaaS technology announces its financial results for the six months ended June 30, 2020.

A complete set of Financial Statements and Management’s Discussion & Analysis will be filed on SEDAR (www.sedar.com) on August 31, 2020. A call to discuss the financial results has been scheduled for Monday, August 31, 2020 at 4:30pm (EST). See details below.

“In Q2 2020 we were able to navigate the complex business challenges presented by COVID-19 and make important strategic advances while maintaining positive EBITDA and cash flow from operations,” says Paul Ghezzi, CEO. “This environment has made it challenging to gain access to customer sites for projects; however, our recurring revenue and service platform have performed very well. In addition, we initiated the development of the Kontrol BioCloud, a new technology designed to detect and alert for the COVID-19 virus. We continue to fund all BioCloud development through internal cash generation. Kontrol does not need to raise capital to operate its business.”

Subsequent to the second quarter end, the Company completed the acquisition of New Found Air (“NFA”) – a building service and solutions company. The operations of NFA are in the process of being merged with Kontrol’s existing platform. NFA expands Kontrol’s building footprint and provides an established customer base with a potential significant cross-selling platform for Kontrol’s smart building technology.

Q2 2020 Financial Summary

Strengthened Financial Position

Kontrol continues to focus on strengthening its Balance Sheet. The Company’s cash position at the end of Q2 is approximately $1.8 Million. During the second quarter of 2020 the Company announced the commencement of a non-brokered private placement (with an exchange of units) of up to $5.8 million principal amount 8% unsecured (and non-convertible) debentures maturing on October 31, 2022. The Company intends to allocate up to $5.8 million of the units for issuance to holders of 2020 debenture units who wish to exchange their 2020 debenture units for units in the offering. The Company anticipates that the majority of unitholders will exchange their units in the months of September and October.

The Company closed the first tranche of non-brokered private placement for 2023 Convertible Debenture Proceeds in the second quarter of net $1.05 million and an additional approximate $900,000 subsequent to the second quarter. The completion of the financing was primarily allocated to the closing of the NFA acquisition

FY 2020 Outlook

The Company continues to strategically focus on the growth of its recurring revenues. With the recently completed acquisition of NFA and the existing customer base, approximately 30% of all revenues are now recurring. The Company’s goal is to drive recurring revenues towards 50% of all total revenues by the end of 2021.

While there appears to be a general improvement with site access to customer facilities there is also ongoing uncertainty presented by COVID-19 travel restrictions and self-quarantine. These conditions make it difficult to forecast project revenues and provide any guidance. Any previous guidance will be retracted, and the Company will continue to provide ongoing reporting and announce larger project revenues as they are generated.

Kontrol BioCloud

The Company is developing its BioCloud technology and has a achieved a number of significant milestones, including the initial funding from the Government, positive testing of the detection mechanism, and positive testing of the BioCloud fully operational prototype. The Company seeks to complete testing with the live COVID-19 virus during the week of August 31 and will provide those results when available. The Company’s objective is to have BioCloud commercially available to potential customers in 2020. There is no assurance that the Company can achieve this internal goal.

About Kontrol BioCloud

BioCloud is a real-time analyzer developed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

* Adjusted EBITDA is a non-IRFS financial measure. The Company defines Adjusted EBITDA as net income or loss before interest, income taxes, amortization, and depreciation, share based compensation, and acquisition related expenses.

Conference Call Details:

Title:	Kontrol Energy Second Quarter 2020 Financial Results
Event Date:	Monday, August 31, 2020 – 4:30PM Eastern Time
Event Duration:	60 Minutes
Event Link:	Webcast URL https://www.webcaster4.com/Webcast/Page/2402/37011
Participant Number:	Toll Free: 877-407-0782 International: 201-689-8567

Please connect at least 5 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast.

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Kontrol Energy is one of Canada’s fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean’s.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

Certain information included in this press release, including information relating to future financial or operating performance and other statements that express the expectations of management or estimates of future performance constitute “forward-looking statements”. Such forward-looking statements include, without limitation, statements regarding possible future acquisitions and/or investments in operating businesses and/or technologies, accelerated organic growth, Adjusted EBITDA, expansion of smart energy technologies into US markets, strategic partnerships to expand into North American Markets, acceleration of recurring SaaS revenues, the provision of solutions to customers and Greenhouse Gas emissions reductions, proposed financial savings and sustainable energy benefits and energy monitoring. Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief are based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that suitable businesses and technologies for acquisition and/or investment will be available, that such acquisitions and or investment transactions will be concluded, that sufficient capital will be available to the Company, that technology will be as effective as anticipated, that organic growth will occur, and others.. However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications. Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and the Company does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise, except as required under applicable securities law.

SOURCE: Kontrol Energy Corp.

Tags: BioCloud, COVID-19, CSE, energy conservation, google nest, stocks, tsx, tsx-v
Posted in Kontrol Energy Corp. | Comments Off on Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Reports Second Quarter 2020 Results $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

AGORACOM Welcomes FansUnite $FANS.ca The Small Cap iGaming Super Company $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

Posted by AGORACOM-JC at 4:51 PM on Monday, August 31st, 2020

The global online gambling market could potentially hit $1 TRILLION by the end of this decade. That is not a typo and the obvious reasons include the following:

1. Exponential growth in the number of people online. Yet only 59% of the world means more to come.

2. Fast growth in the number of countries and jurisdictions legalizing gambling to collect tax revenue.

3. Explosive growth in gambling options beyond casino and sports betting. Fantasy, Esports, etc.

Until recently, however, small-cap investors did not have a company that could provide them ground floor exposure to this massive market and its growth over the next 10 years. The industry was dominated by the big traditional gambling companies, who focus heavily on old fashioned gambling.

That all changes with FansUnite, the small cap iGaming super company that goes beyond simple gambling and attacks both sides of the iGaming market by offering:

B2C (Business To Consumer) Gambling platforms that provide services directly to gamblers

B2B (Business To Business) Gambling technology for companies that already have gamblers

The formation of this iGaming super company became a reality when FansUnite acquired Askott Entertainment recently, the highlights of which are as follows:

$27,000,000 Acquisition
Over $350,000,000 In Total Bets
Over 300,000 Registered Users
Rare combination of B2C + B2B Gambling In Small Cap
- B2C – 4 Platforms
- B2B – 4 Deals Signed; 2 Are Already Live
Askott has integrated over over 6,000 Casino Games Onto Platform
$5,000,000 financing closed in support of acquisition
World renowned team

For those of you who don’t know what Esports is, it can easily be described as the professionalization of video games. Whereas video game players were once stereotyped as basement dwelling geeks, today’s top esports players and teams make millions of dollars competing in online tournaments that are watched by millions of people around the world …. 520,000,000 to be exact.

If you think that number is astounding, consider the fact it will grow to 650,000,000 by 2022.

To put the size of esports into perspective, by 2021, esports is projected to have more viewers than every major sports league in the world except the NFL.

….. AND THEY GAMBLE ….A LOT!

Esports revenues from betting are set to hit record highs in 2020, with revenues expected to double from $7 billion in 2019 to $14 billion, due in no small part to the Covid-19 crisis.

With this massive market up for grabs, the acquisition of Askott provides FANS with a strong opportunity to capture meaningful market share thanks to the following:

Recognized globally as a leader and pioneer in esports betting technology
Launch of the first ever daily fantasy site dedicated to esports
First esports betting site to receive an Isle of Man gaming license in 2017
Shortlisted by EGR Magazine for the Esports Betting Supplier of the Year Award.

WHAT IS THE DIFFERENCE BETWEEN GAMING AND GAMBLING?

The main difference between the terms is that for gaming the outcome is achieved by skill, not chance, whereas for gambling, the opposite is true

THE FANSUNITE LINEUP – B2C

McBookie is a leading provider of betting services under a license to operate granted by the U.K. Gambling Commission. McBookie focuses on B2C offerings and has strategically decided to pursue an underserved market, focusing on the Scottish market and clientele. McBookie has been in operation for over a decade.

10,000 active members
$135M CAD betting volume last 3 years
Sports betting, Casino & Virtual Sports
Delivered a Year over Year increase in Gross Gaming Revenue over the Q2 period of 131%.
- Majority of that has been delivered by the casino where YOY turnover in Q2 was up 59% from $2.4M CAD to $3.9M CAD, resulting in a gross margin increase of 191%.

ESP.BET & ESPORTSPOOLS.com – Esports Betting · Esports Daily Fantasy · Esports Casino

Combined the sites have over 200,000 registered users in 160+ countries
Both using the Chameleon Esports Platform
ESP.bet was the first esports betting site licensed in the Isle of Man
Esportspools.com was the first dedicated esports fantasy site

Latest site to launch on the Chameleon esports betting platform.
LATAM focused brand and an example of the platforms flexibility to launch highly localized sites.
Currently supports 10 languages and can localize to additional languages as needed.

In the hyper growth iGaming world, speed is everything and FANS is on the move in 2020 with partnerships, licenses, acquisitions and new markets in the works, including ENTERING THE US MARKET by the end of this year. Have a look at the FANS roadmap.

FansUnite provides investors with all the elements necessary to earn its place as the leading small cap iGaming company including:

Real Products
Real Customers
Real Revenues
Proven Technology
Rapid Growth
Clear Growth Plan
Global Scalability
Fully Diversified Business With Both B2B and B2C Operations
Powerful Lineup Of Digital Properties
And Last But Not Least For Every Small Cap Company …….. Fully Funded

OVERTIME – THE FANSUNITE LINEUP – IN ACTION

Tags: CSE, EA sports, eGambling, egaming, esports, Fortnite, LOL, poker, sports gambling, sportsbook, stocks
Posted in FansUnite Entertainment Inc., Featured | Comments Off on AGORACOM Welcomes FansUnite $FANS.ca The Small Cap iGaming Super Company $DKNG $PENN $GAN $ESPO $AESE $EGLX.ca $BRAG.ca $FDM.ca

$KABN.ca Profiting from Protection: The Power of Permission-Based Partner Programs $MOS.ca $MOGO.ca $CTZ.ca $PTO.ca $PAY.ca

Posted by AGORACOM-JC at 11:13 AM on Monday, August 31st, 2020

Savvy investors know that lot of smart money is now funneling into forward-thinking companies that are fulfilling an immediate need to provide real world solutions to identity fraud and creating value through data validation.

Now, an innovative, Toronto-based company is making real things happen to protect consumers, companies, and capital.

KABN Systems (CSE.KABN, OTCMKTS: TRWRF, Forum) focuses on the verification, management and monetization of digital identity, empowering users to control and benefit from the use of their online identity. KABN’s propriety technology suite includes four key products – KABN ID, Liquid Avatar, KABN Card, and KABN KASH. The company provides its products and services at no cost to consumers and generates revenues through permission-based partner programs.

In this extremely informative podcast, Stockhouse’s Dave Jackson was joined by KABN’s President, Co-Founder, and Director David Lucatch. Mr. Lucatch has spent more almost 35 years in the international marketing arena and over 25 years of that developing technologies and taking them to market. Prior to co-founding KABN, David held senior management posts and directorships at both private and public technology and media firms.

The Company believes that ownership of identity is a basic human right and individuals should be the primary beneficiary of any use of their identity.

To download episode, click here.

For more infmation, please visit kabnsystemsna.com

Tags: blockchain, canadian fintech, crypto, CSE, kabn cash
Posted in KABN Systems NA Holdings Corp. | Comments Off on $KABN.ca Profiting from Protection: The Power of Permission-Based Partner Programs $MOS.ca $MOGO.ca $CTZ.ca $PTO.ca $PAY.ca

Posts Tagged ‘CSE’

Categories